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One	  Sentence	  Summary:	  G12	  mutant	  KRAS	  requires	  tonic	  ERBB	  network	  activity	  for	  initiation	  
and	  maintenance	  of	  lung	  cancer.	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Abstract:	  KRAS	  is	  the	  most	  frequently	  mutated	  driver	  oncogene	  in	  human	  adenocarcinoma	  of	  
the	  lung.	  There	  are	  presently	  no	  clinically	  proven	  strategies	  for	  treatment	  of	  KRAS-­‐driven	  lung	  
cancer.	   	   Activating	   mutations	   in	   KRAS	   are	   thought	   to	   confer	   independence	   from	   upstream	  
signaling,	  however	  recent	  data	  suggest	  that	  this	  independence	  may	  not	  be	  absolute.	  	  Here	  we	  
show	   that	   initiation	   and	   progression	   of	   KRAS-­‐driven	   lung	   tumors	   requires	   input	   from	   ERBB	  
family	  receptor	  tyrosine	  kinases	  (RTKs):	  	  Multiple	  ERBB	  RTKs	  are	  expressed	  and	  active	  from	  the	  
earliest	   stages	   of	   KRAS-­‐driven	   lung	   tumor	   development,	   and	   treatment	   with	   a	   multi-­‐ERBB	  
inhibitor	  suppresses	  formation	  of	  KRASG12D-­‐driven	  lung	  tumors.	  	  We	  present	  evidence	  that	  ERBB	  
activity	   amplifies	   signaling	   through	   the	   core	   RAS	   pathway,	   supporting	   proliferation	   of	   KRAS-­‐
mutant	  tumor	  cells	  in	  culture	  and	  progression	  to	  invasive	  disease	  in	  vivo.	  	  Brief	  pharmacological	  
inhibition	   of	   the	   ERBB	   network	   enhances	   the	   therapeutic	   benefit	   of	   MEK	   inhibition	   in	   an	  
autochthonous	   tumor	   setting.	   	   Our	   data	   suggest	   that	   lung	   cancer	   patients	   with	   KRAS-­‐driven	  
disease	  may	   benefit	   from	   inclusion	   of	  multi-­‐ERBB	   inhibitors	   in	   rationally	   designed	   treatment	  
strategies.	  	  




Cancers	   of	   the	   lung	   account	   for	   over	   1.5	   million	   deaths	   per	   annum	   worldwide,	   and	   5-­‐year	  
survival	   rates	  remain	  between	  10	  and	  15%	   in	  many	  developed	  countries	   [1].	   	  The	  majority	  of	  
lung	  cancers	  are	  classified	  as	  non-­‐small	  cell	  (NSCLC),	  and	  adenocarcinoma	  is	  the	  most	  common	  
histological	   subtype	   of	   NSCLC.	   Activating	   mutations	   in	   KRAS	   occur	   in	   a	   third	   of	   lung	  
adenocarcinoma	  (LuAd)	  cases	  [2].	  RAS	  proteins	  have	  historically	  proven	  to	  be	  elusive	  targets	  for	  
selective	   inhibition,	   although	   the	   recent	   development	   of	   G12	   mutant	   KRAS-­‐selective	   tool	  
compounds	  suggests	  that	  therapeutic	  targeting	  of	  KRAS	  may	  in	  time	  be	  possible	  [3,	  4].	  	  In	  the	  
interim,	  there	  is	  a	  pressing	  need	  to	  develop	  alternative	  strategies	  for	  more	  effective	  treatment	  
of	  KRAS-­‐driven	  disease.	  
	   The	  ERBB	  family	  of	  receptor	  tyrosine	  kinases	  is	  comprised	  of	  4	  members,	  EGFR	  (ERBB1),	  
HER2	   (ERBB2,	   NEU),	   ERBB3,	   and	   ERBB4,	   all	   of	   which	   can	   homo-­‐	   or	   heterodimerize,	   and	  
dimerization	   is	   required	   for	   signaling	   activity.	   	   ERBB	   dimers	   are	   activated	   upon	   binding	   a	  
spectrum	   of	   soluble	   ligands	   including	   EGF,	   epiregulin	   (EREG),	   amphiregulin	   (AREG),	   and	  
neuregulin	   (NRG),	   amongst	   others,	   together	   forming	   a	   network	   for	   ERBB-­‐driven	   signal	  
transduction	   [5].	   EGFR	   is	   a	   well-­‐recognized	   driver	   of	   lung	   adenocarcinoma,	   with	   genetic	  
alterations	   present	   in	   up	   to	   18%	   of	   cases	   [2].	   	   ERBB2	   and	   ERBB3	   are	   highly	   expressed	   in	  
embryonic	  lungs	  of	  humans	  and	  rodents,	  and	  expression	  of	  both	  persists	  into	  adulthood	  [6,	  7].	  	  
Overexpression	  of	  ERBB2	  in	  the	  absence	  of	  gene	  amplification	  is	  common	  in	  human	  LuAd	  [8,	  9],	  
and	   functionality	   of	   ERBB2/ERBB3	   heterodimers	   in	   NSCLC-­‐derived	   cell	   lines	   was	   previously	  
shown	  [10].	  	  Amplification	  of	  any	  of	  the	  4	  ERBB	  RTKs	  is	  associated	  with	  poor	  prognosis	  in	  lung	  
cancer	   [11],	   and	   high	   expression	   of	   the	   promiscuous	   ERBB	   ligand	   EREG	   has	   previously	   been	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linked	  to	  disease	  progression	  and	  aggressive	  phenotypes	   in	  models	  of	  EGFR-­‐	  and	  KRAS-­‐driven	  
lung	  cancer	  [12,	  13].	  
	   In	  a	  wild-­‐type	  setting,	  ligand-­‐activated	  signaling	  through	  ERBB	  RTKs	  activates	  KRAS	  [14].	  
Mutation	   of	   KRAS	   is	   generally	   thought	   to	   confer	   independence	   from	   upstream	   regulation,	   a	  
view	  that	   is	   reinforced	  by	   the	  mutual	  exclusivity	  of	  activating	  mutations	   in	  KRAS	  and	  EGFR	   in	  
LuAd,	  and	  by	  the	  failure	  of	  EGFR-­‐selective	  inhibitors	  to	  show	  therapeutic	  benefit	  against	  KRAS-­‐
driven	   cancers	   [15,	   16].	   	   However,	   several	   recent	   results	   suggest	   that	   the	   independence	   of	  
mutant	  KRAS	  from	  upstream	  signaling	  may	  not	  be	  absolute:	   	   In	  KRAS-­‐mutant	  NSCLC	  cell	   lines,	  
activation	  of	  PI3K	  is	  contingent	  upon	  basal	  activity	  of	  wild-­‐type	  IGFR,	  establishing	  an	  important	  
precedent	  for	  coordination	  of	  oncogenic	  and	  normal	  signal	  transduction	  [17];	  genetic	  deletion	  
of	   EGFR	   was	   shown	   to	   suppress	   development	   of	   KRASG12D-­‐driven	   pancreatic	   ductal	  
adenocarcinoma	   [18,	   19];	   induced	   expression	   of	   ERBB2	   and	   ERBB3	   was	   found	   to	   underlie	  
resistance	  of	  KRAS-­‐mutant	  lung	  and	  colorectal	  cell	  lines	  to	  MEK	  inhibition	  [20].	  Strikingly,	  in	  the	  
latter	   study,	  MEK	   inhibitor-­‐induced	   ERBB2/3	   expression	  was	   associated	  with	   recovery	   of	   ERK	  
phosphorylation	   downstream	   of	   KRAS,	   suggesting	   a	   surprising	   role	   for	   upstream	   signaling	   in	  
sustaining	  pathway	  activity	  despite	  the	  presence	  of	  activated	  KRAS.	  	  	  
	   We	   therefore	   examined	   the	   requirement	   for	   ERBB	   activity	   in	   an	   inducible	   model	   of	  
progressive	   autochthonous	   LuAd,	   driven	   by	   the	   combination	   of	   endogenously	   expressed	  
KRASG12D	   and	  modest	   overexpression	   of	   c-­‐MYC.	   	  We	   present	   evidence	   that	   redundant	   signal	  
transduction	   through	   multiple	   ERBB	   RTKs	   supports	   development	   and	   progression	   of	   mutant	  
KRAS-­‐driven	   lung	   tumors.	   	   Our	   data	   suggest	   that	   front-­‐line	   use	   of	  multi-­‐ERBB	   inhibitors	  may	  
show	  clinical	  benefit	  in	  KRAS-­‐driven	  LuAd.	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Results	  
ERBB	  activity	  is	  required	  for	  KRasG12D-­‐driven	  lung	  tumor	  formation	  
Induced	   expression	   of	   ERBB-­‐family	   receptor	   tyrosine	   kinases	   (RTKs)	   is	   associated	   with	  
resistance	   of	   KRAS-­‐mutant	   NSCLC	   cell	   lines	   to	  MEK	   inhibition	   [20].	   	  We	   therefore	   examined	  
expression	  of	  ERBB	  RTKs	  and	  their	   ligands	   in	  micro-­‐dissected	  early-­‐stage	   lung	  tumors,	  using	  a	  
CRE-­‐inducible	   mouse	   model	   of	   autochthonous	   lung	   adenocarcinoma	   driven	   by	   KRASG12D	  
combined	   with	   modestly	   increased	   MYC	   (lsl-­‐KRasG12D;Rosa26-­‐lsl-­‐MYC	   –	   henceforth	   KM),	   the	  
latter	  expressed	  from	  the	  Rosa26	  locus	  in	  amounts	  that	  alone	  fail	  to	  provoke	  a	  phenotype	  (fig.	  
S1A).	  	  In	  tumor	  samples	  harvested	  6	  weeks	  after	  allele	  activation,	  we	  found	  strong	  expression	  
of	  Erbb2	  and	  Erbb3	  mRNA,	  whereas	  Egfr	  was	  weakly	  expressed,	  and	  Erbb4	  was	  not	  detected	  in	  
tumors	  from	  2	  of	  4	  KM	  mice	  (Fig.	  1A).	  	  Multiple	  ERBB	  ligands	  were	  expressed,	  with	  Areg,	  Tgfα,	  
and	  Hbegf	   showing	   strongest	   expression,	   while	   Egf,	   Ereg,	  Nrg3,	   and	  Nrg4	   were	   also	   clearly	  
detected	   (Fig.	   1B).	   	   The	   presence	   of	   both	   RTKs	   and	  multiple	   cognate	   ligands	   suggested	   that	  
ERBB	   RTKs	  may	   actively	   signal	   in	   developing	   KRASG12D-­‐driven	   lung	   tumors.	   	   Lysates	   prepared	  
directly	  from	  multiple	  individual	  tumors,	  harvested	  6	  weeks	  after	  induction	  and	  immunoblotted	  
for	   phospho-­‐ERBB	   RTKs,	   consistently	   showed	   readily	   detectable	   phospho-­‐EGFR,	   phospho-­‐
ERBB2,	   and	   phospho-­‐ERBB3,	   suggesting	   that	   these	   RTKs	   are	   indeed	   active	   in	   developing	  
KRASG12D-­‐driven	   lung	   tumors	   (Fig.	   1C	  &	   fig.	   S1B).	   To	   determine	   if	   ERBB	   signaling	   functionally	  
contributes	  to	  tumor	  development,	  we	  treated	  tumor-­‐bearing	  mice	  acutely	  with	  a	  multi-­‐ERBB	  
inhibitor,	   neratinib	   [21].	   	   Treatment	   of	  mice	   for	   3	   days	  with	   neratinib	   suppressed	   activity	   of	  
ERBB	   RTKs,	   reduced	   tumor	   cell	   proliferation,	   and	   increased	   apoptosis,	   suggesting	   that	   ERBB	  
activity	  promotes	  growth	  of	  KRASG12D-­‐driven	  tumors	  (Fig.	  1D-­‐F).	  	  Continuous	  daily	  treatment	  of	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mice	   from	   2	   weeks	   after	   allele	   induction	   almost	   completely	   suppressed	   the	   emergence	   of	  
tumors,	  indicating	  that	  the	  combination	  of	  endogenously	  expressed	  KRASG12D	  and	  constitutively	  
expressed	  MYC	  requires	  input	  from	  ERBB	  RTKs	  in	  order	  to	  give	  rise	  to	  lung	  tumors	  (Fig.	  1G,	  H).	  	  
In	   contrast,	   daily	   erlotinib	   treatment	   failed	   to	   show	   the	   same	   effect,	   consistent	  with	   reports	  
that	  EGFR	  inhibition	  in	  isolation	  is	  ineffective	  in	  KRAS-­‐driven	  lung	  cancer	  [15,	  18].	  
	  
Progression	  of	  KRas-­‐driven	  lung	  tumors	  is	  associated	  with	  increased	  ERBB	  network	  expression	  
The	   above	   analysis	  was	   performed	   on	   tumors	   at	   5-­‐6	  weeks	   after	   adeno-­‐CRE-­‐mediated	   allele	  
activation.	  	  At	  this	  time	  after	  induction,	  the	  lungs	  of	  all	   induced	  KM	  mice	  contained	  dozens	  of	  
individual	   tumors	   that	   presented	   with	   uniform	   histology	   resembling	   human	   papillary	  
adenocarcinoma	  in	  situ	  (Fig.	  2A,	  left	  panels).	  	  A	  small	  minority	  of	  tumors	  (2-­‐5%)	  also	  contained	  a	  
second,	   more	   disorganized	   population	   with	   more	   aggressive	   histological	   features,	   including	  
increased	   cytosolic	   and	   nuclear	   volume,	   prominent	   nucleoli,	   and	   increased	   morphological	  
heterogeneity	  (Fig.	  2A,	  right	  panels).	  	  IHC	  analysis	  revealed	  continuous	  expression	  of	  the	  type	  II	  
pneumocyte	   marker	   SPC	   across	   both	   populations	   in	   individual	   tumors,	   suggesting	   that	   the	  
second	  population	  represents	  the	  emergence	  of	  aggressive	  sub-­‐clones	  (fig.	  S1C).	  	  Progression	  of	  
KRASG12D-­‐driven	   lung	   tumors	   to	   more	   aggressive	   disease	   is	   associated	   with	   a	   pronounced	  
increase	  in	  ERK1/2	  phosphorylation	  [22,	  23].	  	  Accordingly,	  IHC	  analysis	  of	  phospho-­‐ERK	  (p-­‐ERK)	  
revealed	  much	  higher	  expression	  of	  p-­‐ERK	  in	  these	  disorganized	  sub-­‐clones	  compared	  with	  the	  
rest	   of	   the	   same	   tumors,	   and	   indeed	   across	   the	   entire	   tumor	   population	   (Fig.	   2A	   &	   B).	   	   By	  
comparison,	   KM	   tumors	   harvested	   at	   4-­‐6	   months	   after	   induction	   showed	   widespread	  
expression	  of	  p-­‐ERK,	  because	  these	  more	  aggressive	  sub-­‐clones	  gradually	  came	  to	  predominate	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(Fig.	   2B,	   bottom	   panel).	   	   Moreover,	   KM	  metastases	   to	   the	   liver	   also	   show	   high	   amounts	   of	  
epithelial	  p-­‐ERK	  staining	  (Fig.	  2C-­‐F).	  
	   Increased	  p-­‐ERK	  was	  previously	  shown	  to	  be	  associated	  with	  amplification	  of	  the	  mutant	  
KRas	   locus	  in	  a	  KP	  lung	  cancer	  model	  wherein	  KRASG12D	  expression	  was	  combined	  with	  loss	  of	  
functional	  p53	  [24].	  	  We	  used	  laser-­‐capture	  micro-­‐dissection	  coupled	  with	  RNA-­‐SEQ	  analysis	  to	  
compare	  gene	  expression	   in	  p-­‐ERKLow	  with	  p-­‐ERKHigh	  KM	  tumor	  regions	  from	  4	   individual	  mice	  
(see	  schematic,	  fig.	  S1D).	  	  Expression	  of	  KRas	  was	  modestly	  higher	  (<	  2	  fold)	  in	  pERKHigh	  tumor	  
regions,	  suggesting	  that	  locus	  amplification	  is	  not	  the	  underlying	  driver	  of	  progression	  in	  the	  KM	  
model	   (Fig.	  3A).	   	  However,	  we	  detected	  a	  sharp	   increase	   in	  expression	  of	  promiscuous	  ERBB-­‐
family	  ligands,	  Ereg	  and	  Areg,	  along	  with	  more	  modest	  increases	  in	  Hbegf	  and	  Tgfα	  	  (Fig.	  3B-­‐D	  
and	  fig.	  S1E).	  	  Increased	  expression	  of	  Ereg	  and	  Areg	  was	  previously	  reported	  to	  be	  associated	  
with	  more	  aggressive	  tumors	  in	  an	  inducible	  model	  of	  KRAS-­‐driven	  mammary	  cancer	  [25]	  and	  in	  
human	  NSCLC	  cells	  enriched	  for	  metastatic	  behavior	  [26].	  	  In	  situ	  hybridization	  revealed	  a	  clear	  
overlap	   between	   expression	   of	   Ereg,	  Areg	   and	   extensive	   phosphorylation	   of	   ERK	   (by	   IHC)	   in	  
tumor	  epithelium,	  confirming	  the	  RNA-­‐SEQ	  data	  (Fig.	  3C	  and	  fig.	  S2A	  &	  B).	  The	  same	  phenotype	  
of	   focal	  progression	   to	  p-­‐ERKhigh	   accompanied	  by	  dramatically	   increased	  Areg	   expression	  was	  
also	  observed	  in	  primary	  lung	  tumors	  upon	  induction	  with	  a	  more	  lineage-­‐restricted	  adeno-­‐SPC-­‐
CRE	   (fig.	  S2A	  &	  B),	  and	   in	   liver	  metastases	  after	   induction	  with	   the	  standard	  adeno-­‐CMV-­‐CRE	  
(Fig.	   3D	   and	   fig.	   S2C),	   arguing	   against	   the	   possibility	   that	   this	   phenotype	   might	   arise	   from	  
inadvertent	   activation	   of	   the	   driver	   oncogenes	   in	   other	   lung-­‐resident	   populations	   [27].	  	  
Additionally,	   RNA-­‐SEQ	   analysis	   revealed	   increased	   expression	   of	   Adam9	   and	   Adam10	  
sheddases,	  which	  process	  membrane-­‐bound	  ERBB	  ligands	  into	  their	  more	  potent	  soluble	  forms	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[28];	  increased	  expression	  of	  the	  signaling	  scaffold	  Iqgap2;	  and	  increased	  expression	  of	  LamC2,	  
Fabp5,	  and	  Keratin19,	  all	  recently	  shown	  to	  enhance	  signaling	  through	  EGFR/ERBB	  family	  RTKs	  
[26,	  29,	  30].	   	  Expression	  of	  Erbb2	  and	  Erbb3	  was	  not	  significantly	  changed	  in	  p-­‐ERKHigh	  regions	  
(Fig.	  3E	  &	  F).	  	  	  
	   These	  data	   suggest	  an	  alternative	   route	   to	   increased	  RAS	  pathway	  signaling	   that	  does	  
not	   require	   KRas	   amplification	   but	   rather	   involves	   increased	   activity	   of	   the	   ERBB	   network,	  
defined	  here	  as	  consisting	  of	  ERBB	  ligands,	  RTKs,	  and	  RTK	  accessory	  molecules	  such	  as	  LamC2	  
and	   Fabp5.	   Notably,	   examination	   of	   the	   TCGA	   lung	   adenocarcinoma	   (LuAd)	   dataset	   via	  
cBioPortal	  [31]	  revealed	  overexpression	  and/or	  amplification	  of	  one	  or	  more	  constituents	  of	  the	  
ERBB	  network	  in	  the	  majority	  of	  KRAS-­‐mutant	  human	  LuAd	  (fig.	  S3).	  	  
	  
ERBB	  signaling	  amplifies	  RAS	  pathway	  activity	  in	  KRAS-­‐mutant	  human	  NSCLC	  cells	  
Combined	   inhibition	   of	   both	   EGFR	   and	   ERBB2	   is	   required	   to	   prevent	   outgrowth	   of	   MEK	  
inhibitor-­‐resistant	  clones	  of	  human	  KRAS-­‐mutant	  NSCLC	  cells,	  however	  the	  effect	  of	  multi-­‐ERBB	  
inhibition	   on	   treatment-­‐naïve	   cells	   was	   not	   previously	   explored	   [20].	   	   Treatment	   of	  multiple	  
KRAS-­‐mutant	   human	   NSCLC	   lines	   with	   the	   multi-­‐ERBB	   inhibitor	   neratinib	   suppressed	  
proliferation	  in	  a	  dose-­‐dependent	  manner	  (Fig.	  4A).	  	  In	  contrast,	  inhibition	  of	  EGFR	  in	  isolation	  
showed	   little	   effect.	   	   Immunoblotting	   confirmed	   that	   the	   doses	   of	   neratinib	   used	   strongly	  
suppressed	   activity	   of	   ERBB	   RTKs	   (Fig.	   4B).	   	   Consistent	   with	   previous	   reports	   that	   neratinib	  
drives	  increased	  ERBB	  turnover	  [32],	  ERBB2	  and	  ERBB3	  protein	  expression	  was	  also	  reduced	  by	  
neratinib	   in	   multiple	   cell	   lines.	   	   Despite	   the	   presence	   of	   G12	   mutant	   KRAS	   in	   all	   such	   cells	  
neratinib	  consistently	   reduced	  phospho-­‐ERK	  whereas	  effects	  on	  AKT	  and	  STAT3	  varied	  across	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the	   cell	   lines	   tested	   (Fig.	   4B	   &	   fig.	   S4A).	   	   We	   therefore	   examined	   RAF	   binding	   as	   a	   direct	  
measure	  of	  RAS	  signaling	  activity	  in	  A549	  cells,	  which	  are	  homozygous	  for	  mutant	  KRAS.	  	  Acute	  
ERBB	   inhibition	   reduced	  both	   total	  RAS:RAF	  &	   specific	  KRAS:RAF	  binding	  by	  >50%,	   consistent	  
with	   the	  observed	  partial	   reduction	   in	   p-­‐ERK	   (Fig.	   4C).	   	   Additionally,	  murine	   lung	   tumor	   cells	  
carrying	   a	   spontaneously	   amplified	   KRasG12D	   allele	   also	   showed	   sensitivity	   to	   neratinib,	   albeit	  
somewhat	   lower	   than	   that	  of	   cells	   carrying	  a	   single	  copy	  of	   the	  allele	   (fig.	  S4B),	  and	  RAS-­‐less	  
MEFs	  reconstituted	  with	  G12D	  mutant	  KRAS	  were	  likewise	  sensitive	  to	  neratinib,	  albeit	  less	  so	  
than	  those	  reconstituted	  with	  wt	  KRAS	  (fig.	  S4C	  &	  D).	  	  Together	  these	  results	  suggest	  that	  ERBB	  
amplifies	  signaling	  through	  the	  core	  RAS-­‐>ERK	  module,	  even	  in	  cells	  with	  activating	  mutation	  of	  
KRAS,	  whereas	  sensitivity	  to	  ERBB	  suppression	  is	  imparted	  through	  both	  mutant	  and	  wild-­‐type	  
KRAS.	  
To	   gain	   further	  mechanistic	   insight	   into	   the	   growth	   inhibitory	   effects	   of	   neratinib,	  we	  
performed	  unbiased	  transcriptomic	  analysis	  after	  overnight	  treatment	  of	  3	  KRAS-­‐mutant	  NSCLC	  
cell	   lines.	  Metacore	   GeneGO	   pathway	   analysis	   revealed	   a	   remarkable	   degree	   of	   consistency	  
across	   the	   3	   cell	   lines	   tested.	   	   Moreover,	   18	   of	   the	   20	   most	   highly	   modulated	   pathways	  
associated	   with	   progression	   of	   murine	   KM	   tumors	   to	   p-­‐ERKHigh	   disease	   were	   reciprocally	  
modulated	  in	  the	  human	  cells	  upon	  neratinib	  treatment	  (Fig.	  4D	  &	  Table	  S1).	  	  	  In	  all	  three	  cell	  
lines,	   ERBB	   inhibition	   reduced	   expression	   of	   the	   same	   ERBB	   ligands	   that	   increased	   as	   KM	  
tumors	   progressed	   to	   p-­‐ERKHigh	   disease	   (Fig.	   4E).	   These	   findings	   indicate	   that	   ERBB	   activity	  
establishes	   a	   feed-­‐forward	   loop	   that	   sustains	   KRAS-­‐mutant	   NSCLC	   proliferation	   in	   vitro	   and	  
drives	  tumor	  progression	  in	  vivo,	  at	  least	  in	  part	  by	  amplifying	  signaling	  through	  the	  core	  RAS-­‐
ERK	  module.	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ERBB	  inhibition	  enhances	  the	  potency	  of	  MEK	  inhibition	  in	  vitro	  and	  extends	  survival	  of	  mice	  
with	  LuAd	  
With	  the	  exception	  of	  H358	  cells,	  ERBB	  inhibition	  alone	  did	  not	  result	  in	  death	  of	  KRAS	  mutant	  
NSCLC	   cells	   in	   vitro,	   however,	   neratinib	   increased	   apoptosis	   induced	   by	   inhibition	   of	   MEK	  
downstream	   of	   KRAS	   in	  multiple	   cell	   lines	   (Fig.	   5A).	   	   Substitution	   of	   neratinib	  with	   a	   second	  
multi-­‐ERBB	   inhibitor,	   afatinib,	   replicated	   the	   effects	   of	   neratinib,	   confirming	   the	   on-­‐target	  
specificity	   of	   the	   drug	   (fig.	   S5A).	   	   Moreover,	   both	   drugs	   combined	   with	   MEK	   inhibition	   to	  
suppress	   colony	   formation	   (Fig.	   5B).	   Consistent	   with	   published	   results	   [20],	   MEK	   inhibition	  
alone	   increased	   expression	   of	   ERBB2	   and	   ERBB3	   in	   vitro,	   although	   the	   effect	   on	   ERBB2	  
phosphorylation	  was	  variable	  across	  the	  cell	  lines	  tested	  (Fig.	  5C).	  	  Co-­‐treatment	  with	  neratinib	  
suppressed	   both	   expression	   and	   activity	   of	   ERBB2	   and	   ERBB3,	   while	   also	   suppressing	   EGFR	  
activity	  (Fig.	  5C).	  	  Downstream	  of	  the	  RTKs,	  trametinib	  alone	  consistently	  suppressed	  expression	  
of	  p-­‐ERK	  and	  c-­‐MYC,	  but	  increased	  phosphorylation	  of	  AKT	  and	  STAT3	  (Fig.	  5C).	  	  Suppression	  of	  
increased	   AKT	   phosphorylation	   by	   neratinib	   was	   clear	   only	   in	   H358	   cells,	   but	   the	   drug	  
combination	  failed	  to	  reduce	  STAT3	  phosphorylation.	  	  The	  growth	  inhibitory	  effects	  of	  the	  drug	  
combination	  in	  vitro	  thus	  better	  correlate	  with	  suppression	  of	  the	  core	  RAS-­‐ERK-­‐MYC	  pathway	  
than	  with	  the	  activity	  of	  ancillary	  signaling	  pathways.	  
The	   combination	  of	  MEK	  and	  multi-­‐ERBB	   inhibition	  was	  previously	   shown	   to	   suppress	  
the	  growth	  of	  subcutaneous	  NSCLC	  xenografts	  under	  continuous	  daily	  treatment	  [20],	  however,	  
cell	  line	  xenografts	  have	  a	  poor	  track	  record	  of	  accurately	  predicting	  human	  patient	  responses.	  	  
We	  therefore	  tested	  the	  therapeutic	  efficacy	  of	  transient	  inhibition	  of	  ERBB	  and/or	  MEK	  in	  our	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fully	   immunocompetent	   KM	   model	   of	   autochthonous	   lung	   adenocarcinoma.	   	   Tumors	   were	  
induced	   in	  adult	  KM	  mice	  and	  allowed	  to	  develop	  for	  6	  weeks.	   	  The	  presence	  of	  an	   IRFP	  Cre-­‐
reporter	  allele	  [33]	  in	  a	  subset	  of	  such	  animals	  allowed	  us	  to	  confirm	  the	  presence	  of	  tumors	  by	  
Licor	  PEARL	  fluorescence	  imaging	  before	  initiating	  therapy	  (fig.	  S5B).	   	  Mice	  were	  treated	  daily	  
for	   1	   week	   with	   neratinib,	   alone	   or	   in	   combination	   with	   trametinib,	   then	   left	   untreated	   to	  
determine	  the	  effect	  on	  overall	  survival.	  	  Transient	  ERBB	  blockade	  alone	  showed	  little	  influence	  
on	   overall	   survival,	   whereas	   MEK	   inhibition	   alone	   extended	   survival	   of	   KM	   mice.	   The	  
combination	  of	  neratinib	  and	  trametinib	  further	  extended	  survival	  over	  that	  achieved	  by	  MEK	  
inhibition	  alone	  (Fig.	  5D).	  Fluorescence	  imaging	  of	  IRFP-­‐positive	  KM	  mice	  showed	  pronounced	  
suppression	  of	  lung	  tumor	  growth	  in	  individual	  mice	  treated	  with	  combination	  therapy	  (fig.	  S5B	  
&	  C).	   	   Immunoblotting	  of	  tumors	  from	  mice	  treated	  for	  3	  days	  with	  either	  drug	  alone	  or	  both	  
combined	   confirmed	   the	   pathway-­‐specific	   effects	   of	   these	   inhibitors	   in	   vivo	   (Fig.	   5E).	   	   We	  
conclude	   from	   these	   data	   that	  multi-­‐ERBB	   inhibition	  may	   benefit	   LuAd	   patients	  with	  mutant	  
KRAS-­‐driven	  disease,	  if	  used	  in	  combination	  with	  other	  agents	  such	  as	  MEK	  inhibitors.	  
Kruspig et al. 
 13 
Discussion	  	  
EGFR-­‐selective	  inhibitors	  have	  failed	  to	  show	  clinical	  benefit	  in	  mutant	  KRAS-­‐driven	  cancers.	  In	  
contrast	  with	  targeted	  inhibition	  of	  EGFR	  in	  isolation,	  we	  show	  here	  that	  broad	  inhibition	  of	  the	  
ERBB	   network,	   using	   the	   multi-­‐ERBB	   inhibitor	   neratinib,	   almost	   completely	   suppresses	  
formation	   of	   KRASG12D-­‐driven	   lung	   tumors,	   and	   enhances	   the	   benefit	   of	   MEK	   inhibition	   in	  
established	  tumors.	  	  We	  show	  that	  ERBB	  activity	  enhances	  signaling	  through	  the	  core	  RAS-­‐>ERK	  
pathway,	  establishing	  a	  feed-­‐forward	   loop	  that	   is	  associated	  with	  progression	  to	   invasion	  and	  
metastasis.	   	   We	   also	   show	   that	   brief,	   transient	   inhibition	   of	   ERBB	   signaling	   enhances	   the	  
therapeutic	  benefit	  of	  MEK	  inhibition	  in	  the	  autochthonous	  setting.	  Although	  this	  latter	  result	  is	  
broadly	  supportive	  of	  the	  clinical	  implications	  of	  an	  earlier	  study	  showing	  that	  increased	  ERBB	  
activity	  underlies	  resistance	  to	  MEK	  inhibition	  [20],	  our	  data	  are	  fundamentally	  distinct	  in	  that	  
we	   demonstrate	   a	   clear	   role	   for	   ERBB	   activity	   from	   the	   very	   outset	   of	   KRAS-­‐driven	   tumor	  
initiation,	  as	  opposed	  to	  in	  reaction	  to	  targeted	  inhibition	  of	  MEK.	  	  
	   Mechanistically,	   we	   show	   that	   nascent	   KRasG12D-­‐driven	   lung	   tumors	   express	   multiple	  
ERBB	  ligands	  and	  that	  production	  of	  these	  ligands	  increases	  dramatically	  as	  tumors	  progress	  to	  
more	  aggressive	  disease.	  In	  the	  cell	  culture	  setting,	  the	  release	  of	  these	  ligands	  drives	  autocrine	  
signaling	  that	  supports	  the	  viability	  of	  cancer	  cells.	  	  In	  vivo,	  the	  release	  of	  such	  ligands	  into	  the	  
extracellular	  milieu	   likely	  drives	  both	  autocrine	  and	  paracrine	   signal	   transduction	   in	  any	   local	  
cell	  population	  that	  expresses	  ERBB	  RTKs.	  	  As	  such,	  it	  is	  plausible	  to	  consider	  that	  some	  of	  the	  
tumor-­‐suppressive	   benefit	   of	   neratinib	  may	   derive	   from	   inhibition	   of	   ERBB	   signaling	   in	   such	  
stromal	   populations.	  Nevertheless,	   our	   cell	   culture	   analysis	   argues	   that	   the	   primary	   effect	   of	  
ERBB	  inhibition	  is	  indeed	  autonomous	  to	  the	  tumor	  epithelium.	  	  Further	  work	  will	  be	  needed	  to	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determine	  if	  paracrine	  activation	  of	  ERBB	  RTKs	  on	  attendant	  stromal	  cell	  populations	  plays	  any	  
role	  in	  tumor	  maintenance	  or	  progression.	  
Previous	   work	   has	   revealed	   that	   threshold	   levels	   of	   KRAS	   signaling	   are	   required	   for	  
tumor	   initiation	   and	   progression:	   In	   an	   inducible	   model	   of	   HRASG12V	   overexpression	   in	  
mammary	   glands,	   focal	   tumors	   arising	   spontaneously	   from	   non-­‐transformed	   epithelium	   that	  
expressed	  low	  amounts	  of	  the	  transgene	  exhibited	  a	  pronounced	  increase	  in	  expression	  of	  both	  
the	  HRasG12V	   transgene	   and	   of	  multiple	   ERBB	   ligands,	   including	   Ereg,	   Tgfa,	   and	  Hbegf,	   again	  
suggestive	   of	   feed-­‐forward	   signal	   amplification	   [25].	   More	   recently,	   this	   same	   “activity	  
threshold”	  principle	  was	  shown	  to	  apply	  to	  ERK	  signaling	  as	  the	  key	  oncogenic	  effector	  pathway	  
of	   KRAS	   in	   the	   lung	   [34].	   Through	   pharmacological	   enhancement	   of	   ERK	   activity,	   this	   study	  
showed	  that	  different	  airway	  cell	  types	  require	  distinct	  amounts	  of	  ERK	  signaling	  for	  oncogenic	  
transformation	   by	  mutant	   KRAS,	   and	   that	   a	   second,	   higher,	   threshold	   signal	  was	   needed	   for	  
progression	   to	   carcinoma.	   The	   existence	   of	   this	   higher	   threshold	   in	   KRAS-­‐driven	   LuAd	   was	  
already	   clear	   from	   the	   pronounced	   increase	   in	   ERK	   phosphorylation	   associated	   with	   tumor	  
progression	   [25]	  which,	   in	   the	  KP	  model,	   is	  driven	  by	   spontaneous	  amplification	  of	   the	  G12D	  
mutated	  allele	  [24].	  	  Our	  data	  suggest	  that	  ratcheting	  up	  ERBB	  signal	  transduction	  provides	  an	  
alterative	  route	  to	  RAS	  pathway	  signal	  amplification,	  independent	  of	  KRAS	  gene	  amplification.	  	  
It	   is	   important	   to	   note	   that,	   from	   the	   human	  data,	   there	   does	   not	   appear	   to	   be	   a	   preferred	  
mechanism	   of	   ERBB	   signal	   enhancement	   –	   overexpression	   of	   ligands,	   amplification	   of	   RTKs,	  
and/or	   accessory	   molecules	   could	   all	   plausibly	   achieve	   the	   same	   effect.	   What	   is	   clear	   from	  
these	  data	  is	  that	  the	  potential	  to	   increase	  ERBB	  signaling	  appears	  to	  be	  widespread	  in	  KRAS-­‐
mutant	  human	  LuAd.	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   Perhaps	   the	   most	   surprising	   observation	   is	   that	   endogenously	   expressed	   KRASG12D	  
requires	   basal	   signaling	   from	  ERBB	  RTKs	   to	   initiate	   lung	   tumors,	   even	  when	   accompanied	  by	  
MYC	  overexpression.	  We	  previously	  showed	  that	  expression	  from	  the	  Rosa26	  locus	  is	  refractory	  
to	   growth	   factor	   signaling	   [35]	   –	   thus	   the	   requirement	   for	   ERBB	   activity	   does	   not	   reflect	   an	  
artificial	   need	   for	   ERBB	   to	   sustain	   expression	   of	   the	   MYC	   transgene,	   whereas	   the	   observed	  
effects	   on	   total	  MYC	   expression	   likely	   reflect	   the	   influence	   of	   RAS	   signaling	   on	  MYC	   protein	  
stability	  [36].	  	  Instead,	  these	  data	  suggest	  that	  G12	  mutant	  KRAS	  requires	  a	  push	  from	  upstream	  
RTKs	  to	  breach	  the	  initial	  threshold	  needed	  for	  tumor	  initiation.	  	  Supporting	  this	  hypothesis,	  it	  
was	  recently	  shown	  that	  G12	  mutant	  KRAS,	  although	  no	  longer	  responsive	  to	  RAS-­‐GAPs,	  does	  
retain	  some	  level	  of	  intrinsic	  GTPase	  activity	  and	  thus	  cycles	  slowly	  between	  on	  and	  off	  states	  
[4],	   opening	   the	   possibility	   for	   upstream	   signaling	   to	   influence	   activity,	   either	   directly	   or	   by	  
promoting	  activity	  of	  RAS	  guanonucleotide	  exchange	  factors	  (GEFs).	  	  Alternatively,	  tonic	  signal	  
transduction	   through	   wild-­‐type	   RAS	   isoforms	   may	   need	   to	   combine	   with	   that	   from	   mutant	  
KRAS	   to	   likewise	   breach	   the	   threshold	   for	   transformation	   [37].	   	   Our	   data	   presently	   do	   not	  
distinguish	  between	  these	  possibilities	  and,	  indeed,	  they	  may	  not	  be	  mutually	  exclusive.	  
In	  the	  course	  of	  preparing	  this	  manuscript	  we	  became	  aware	  of	  an	   independent	  study	  
that	   strongly	   complements	   our	   observations	   and	   underscores	   our	   conclusions:	   The	   work	   by	  
Moll	   and	   colleagues	   similarly	   demonstrates	   a	   requirement	   for	   ERBB	   signaling	   to	   support	  
progression	  of	  KRASG12D-­‐driven	  lung	  cancer	  in	  vivo	  [38].	  	  Their	  study	  used	  an	  independent	  pan-­‐
ERBB	  inhibitor,	  afatinib,	  in	  the	  context	  of	  both	  KRASG12D-­‐only	  and	  KRASG12D;p53Fl/Fl	  -­‐driven	  tumor	  
models.	   	  The	  striking	  similarities	   in	  the	  two	  studies	  attest	   to	  the	  on-­‐target	  specificity	  of	   the	  2	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drugs	  used,	  while	  also	  showing	  that	  the	  effects	  are	  independent	  of	  the	  genetic	  strategy	  used	  to	  
accelerate	  KRAS-­‐driven	  disease	  and	  are	  therefore	  likely	  to	  have	  broader	  potential	  application.	  
Activating	   mutations	   in	   KRAS	   are	   currently	   considered	   grounds	   for	   exclusion	   from	  
clinical	   treatment	  with	   EGFR/ERBB	   inhibitors,	   and	   single-­‐agent	   trials	   of	   the	   same	   drugs	   have	  
only	   demonstrated	   efficacy	   in	   patient	   cohorts	   with	   activating	   mutations	   in	   EGFR	   or	   ERBB	  
amplification	   [39].	   	   Indeed,	  our	  data	   concur	   that	  multi-­‐ERBB	   inhibitors	  are	  unlikely	   to	  benefit	  
KRAS-­‐driven	  cancer	  patients	  if	  used	  in	  isolation.	  	  However,	  we	  show	  here	  the	  potential	  for	  such	  
drugs	  to	  sensitize	  autochthonous	  KRAS-­‐driven	  tumors	  to	  additional	  therapeutic	  agents,	   in	  this	  
case	  to	  the	  MEK	  inhibitor	  trametinib.	  	  Our	  data	  argue	  that	  clinical	  use	  of	  multi-­‐ERBB	  inhibitors	  
as	  part	  of	  an	  inhibitor	  cocktail	  to	  treat	  KRAS-­‐driven	  LuAd	  deserves	  re-­‐examination.	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Materials	  and	  Methods	  
Study	   Design:	   Rationale	   for	   the	   project	   was	   to	   investigate	   the	   mechanistic	   basis	   of	   tumor	  
progression	   in	   early	   stage	   KRAS-­‐driven	   lung	   cancer.	   Unbiased	   RNA-­‐SEQ	   analysis	   identified	  
increased	   expression	   of	   the	   ERBB	   network,	   prompting	   further	   mechanistic	   investigation.	   All	  
mice	  were	  asymptomatic	  at	   the	  date	  of	   treatment	   initiation	  and	  were	  allocated	  to	   treatment	  
groups	   randomly.	   For	   survival	  benefit	   analysis,	   the	  absence	  of	  prior	  data	  precluded	  a	  precise	  
power	  calculation:	  Sample	  sizes	  were	  therefore	  estimated	  according	  to	  Lehr’s	  quick	  formula	  at	  
80%	  power	   {n=16(c.v.)2(ln[r.m.])2},	   assuming	  a	   ratio	  of	   the	  means	  of	  0.2	  and	  a	   coefficient	  of	  
variation	  of	  0.3.	   	  For	  all	  other	  analyses,	  sample	  sizes	  were	  determined	  in	  accordance	  with	  the	  
3Rs.	  Animals	  were	  treated	  by	  facility	  staff	  without	  knowledge	  of	  anticipated	  outcomes.	  Humane	  
endpoints	  were	  predefined	  as	   impaired	  breathing	  and/or	  hunching	  with	  10%	  or	  more	  weight	  
loss.	   Histology,	   IHC	   and	   ISH	   were	   performed	   blindly	   by	   the	   Beatson	   Institute	   histology	   core	  
facility	   and	   were	   scored	   without	   reference	   to	   genotype	   or	   treatment	   group.	   Reporting	   is	  
consistent	  with	  the	  ARRIVE	  guidelines.	   In	  vitro	  experiments	  were	  all	  performed	  on	  3	  separate	  
occasions,	  except	  where	  noted.	  	  In	  vitro	  analyses	  were	  not	  blinded.	  
	  
Genetically	  Engineered	  Mice	  &	  Mouse	  Procedures:	  Procedures	  involving	  mice	  were	  performed	  
in	   accordance	  with	  Home	  Office	   license	   numbers	   60/4183	  &	  70/7950	   (CRUK	  BICR,	  UK).	   	   LSL-­‐
KRasG12D	   (B6.129S4-­‐Krastm4Tyj/J)	   mice	   [40]	   were	   obtained	   from	   the	   NCI	   mouse	   repository	   at	  
Frederick,	  MD,	  USA.	  Rosa26DM.lsl-­‐MYC	  mice	  were	  generated	  as	  previously	  described	  [35]	  with	  the	  
ATG-­‐initiated	   human	   c-­‐MYC	   (MYC2)	   cDNA,	   devoid	   of	   5'	   and	   3'	   UTRs,	   replacing	   the	   MYC-­‐
estrogen	  receptor	  ligand-­‐binding	  domain	  fusion	  cDNA.	  Targeted	  insertion	  into	  the	  Rosa26	  locus	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was	  confirmed	  by	  Southern	  blotting,	  and	  genotyping	  was	  initially	  performed	  with	  the	  following	  
primers:	   A)	   CCC	   AAA	   GTC	   GCT	   CTG	   AGT	   TG	   (common);	   B)	   GCG	   AAG	   AGT	   TTG	   TCC	   TCA	   ACC	  
(targeted	   locus);	  C)	  GGA	  GCG	  GGA	  GAA	  ATG	  GAT	  ATG	  A	  (wild-­‐type	   locus).	  All	  genotyping	  was	  
subsequently	   performed	   by	   Transnetyx	   Inc.	   	   Detailed	   in	   vivo	   procedures	   are	   provided	   in	   the	  
supplemental	   material	   along	   with	   immunohistochemical,	   laser-­‐capture	   microdissection	   and	  
RNA-­‐SEQ	  methodology.	  
	  
Cell	  Culture	  and	  Related	  Assays	  
Human	  lung	  cancer	  cell	  lines	  (A549,	  H2009,	  H358)	  were	  validated	  in-­‐house	  and	  grown	  in	  RPMI	  
with	   10%	   FBS	   and	   penicillin	   (100	   units/ml)/streptomycin	   (100µg/ml).	   RAS-­‐less	   MEFs	  
reconstituted	  with	  wild-­‐type	   or	  mutant	   KRAS	   isoforms	  were	   generously	   provided	   by	   the	  NCI	  
RAS	  Initiative,	  Frederick	  National	  Laboratory	  for	  Cancer	  Research,	  MD,	  USA,	  and	  were	  cultured	  
in	  DMEM	  supplemented	  with	  10%	  FBS	  and	  penicillin	   (100	  units/ml)/streptomycin	   (100µg/ml).	  	  
For	   immunoblotting,	  cells	  were	  lysed	  in	  RIPAHi	  buffer	  (150	  mM	  NaCl,	  50	  mM	  Tris	  [pH	  7.5],	  1%	  
NP-­‐40,	   0.5%	   sodium	  deoxycholic	   acid,	   1%	   SDS	  plus	   Complete	   protease/phosphatase	   inhibitor	  
cocktails	   [Sigma-­‐Aldrich])	   and	   after	   western	   blotting,	   probed	   with	   the	   following	   primary	  
antibodies:	  p-­‐ERK	  Thr202;Tyr204	  (E-­‐4),	  Santa	  Cruz	  SC7383;	  p-­‐EGFR	  Tyr1068,	  Cell	  Signaling	  3777;	  
p-­‐ERBB2	  Tyr	  1248,	  Millipore	  06-­‐229;	  p-­‐ERBB3	  Tyr	  1197	  Cell	  Signaling	  4561;	  ERK1/2	  Cell	  Signaling	  
4695;	   EGFR	  Millipore	  06-­‐847;	   ERBB2	  Merck	  OP15L;	   ERBB3	  Millipore	  05-­‐390.	  RAS:RAF	  binding	  
assays	  were	   performed	   using	   a	   commercial	   RAS	   activity	   assay	   kit	   (Cytoskeleton)	   and	   probed	  
with	  pan-­‐RAS	  (AESA02,	  Cytoskeleton),	  KRAS	  (SC-­‐30,	  Santa	  Cruz),	  or	  HRAS-­‐specific	  (18295-­‐1-­‐AP,	  
Proteintech)	  antibodies	  [41].	  	  Cell	  propagation	  and	  death	  were	  analyzed	  by	  Incucyte	  time-­‐lapse	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video-­‐microscopy	   in	   the	   presence	   of	   Sytox	   green.	   Cell	   death	  measurements	  were	   performed	  
after	  48	  hours	  of	  drug	  treatment	  and	  corrected	  for	  confluence.	  	  
	  
Statistical	  Analysis	  
Raw	  data	   obtained	   from	  quantitative	   Real	   Time	  PCR,	   FACS,	   and	   Incucyte	   assays	  were	   copied	  
into	  Excel	  (Microsoft)	  or	  Prism	  (Graphpad)	  spreadsheets.	  	  All	  mean	  values,	  SD,	  and	  SEM	  values	  
of	  biological	  replicates	  were	  calculated	  using	  the	  calculator	  function.	  Graphical	  representation	  
of	   such	  data	  was	  also	  produced	   in	  Excel	  or	   in	  Prism.	   	  Statistical	   significance	   for	  pairwise	  data	  
was	   determined	   by	   the	   Student’s	   T	   test.	   For	  multiple	   comparisons,	   ANOVA	  was	   used	  with	   a	  
post-­‐hoc	  Tukey	  test.	  	  *	  denotes	  P<0.05;	  **	  denotes	  P<0.01;	  ***	  denotes	  P<0.001.	  	  For	  Kaplan-­‐
Meier	  plots,	  log	  rank	  P	  values	  are	  presented.	  	  	  
 




Supplementary	  Figures	  and	  Tables:	  
Fig.	  S1.	  Characterization	  of	  KM	  lung	  tumors.	  	  	  
Fig.	  S2.	  Comparison	  of	  KM	  phenotype	  induced	  by	  Ad-­‐CMV-­‐CRE	  &	  Ad-­‐SPC-­‐CRE.	  	  	  
Fig.	  S3.	  Genomic	  alterations	  and	  expression	  of	  ERBB	  network	  genes	  in	  human	  KRAS-­‐mutant	  lung	  
adenocarcinoma.	  	  	  
Figure	  S4.	  Sensitivity	  of	  KRAS	  mutant	  cell	  lines	  to	  ERBB	  blockade.	  	  	  
Figure	  S5.	  Longitudinal	  in-­‐vivo	  imaging	  of	  nascent	  lung	  tumors.	  	  	  
Table	  S1.	  Summary	  of	  Metacore	  GeneGO	  pathway	  analysis.	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Figure	  1:	  ERBB	  activity	  is	  required	  for	  KRAS-­‐driven	  lung	  tumor	  formation	  
A)	  Expression	  of	  ERBB	  family	  RTKs	  in	  KM	  lung	  tumors	  harvested	  6	  weeks	  post	  allele	   induction	  
(PI),	   measured	   by	   RNA-­‐SEQ.	   	   Mean±SD	   read	   counts	   in	   tumors	   from	   4	   mice	   shown.	   	   B)	  
Expression	   of	   ERBB	   family	   ligands	   in	   KM	   lung	   tumors	   harvested	   6	   weeks	   PI,	   as	   per	   (A).	   	   C)	  
Immunoblots	  of	   lysates	  generated	  from	  10	  individual	  KM	  tumors,	  harvested	  6	  weeks	  PI,	  using	  
the	  indicated	  antibodies.	   	  D)	  Representative	  images	  of	  IHC	  for	  Ki67	  and	  TUNEL	  staining	  of	  KM	  
mice	  treated	  for	  3	  days	  with	  80	  mg/kg	  neratinib	  (n=3)	  or	  vehicle	  control	  (n=3).	  	  Scale	  bars	  =	  100	  
µm.	  	  E)	  Quantification	  (mean	  ±	  SEM)	  of	  staining	  in	  5	  tumors	  from	  each	  mouse	  as	  per	  (D).	  	  Left	  
panel	   shows	  %	  of	   tumor	   cells	   expressing	   Ki67;	   right	   panel	   shows	  %	  of	   TUNEL-­‐positive	   tumor	  
cells;	   	  vc	  =	  vehicle	  control.	   	  P	  values	  are	  from	  2-­‐tailed	  T	  tests.	   	  F)	   Immunoblots	  of	  3	   individual	  
KM	  tumors	  from	  mice	  treated	  for	  3	  days	  with	  neratinib	  or	  vehicle	  control.	   	  G)	  Representative	  
H&E	   images	   from	   KM	  mice	   treated	   daily	   with	   neratinib	   (2	   x	   40	   mg/kg)	   or	   erlotinib	   (2	   x	   50	  
mg/kg),	   commencing	   2	   weeks	   PI,	   and	   harvested	   at	   6	   weeks	   PI.	   	   Scale	   bar	   =	   1	   mm.	   	   H)	  
Quantification	  of	  tumor	  burden	  from	  (G).	  Box	  and	  whisker	  plots	  show	  median,	  interquartile	  and	  
99%	  range	  of	  tumor	  area,	  expressed	  as	  a	  percentage	  of	  total	  lung	  tissue	  area,	  measured	  across	  
>25	   sections	   from	   each	  mouse.	   N	   =	   5	   vehicle	   control	   (vc);	   n	   =	   4	   erlotininb;	   n	   =	   3	   neratinib.	  
ANOVA	  followed	  by	  Tukey	  test,	  	  ns=not	  significant.	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Figure	  2:	  KM	  lung	  tumor	  progression	  is	  associated	  with	  increased	  ERK	  phosphorylation	  
A)	   Images	   of	   H&E	   (upper	   panels)	   and	   phospho-­‐ERK	   (lower	   panels)	   stained	   KM	   lung	   tumors	  
harvested	  at	  6	  weeks	  PI	  illustrating	  histological	  changes	  associated	  with	  tumor	  progression:	  left	  
panels	   are	   representative	   of	   >95%	   of	   total	   tumor	   area	   at	   6	   weeks	   PI,	   while	   right	   panels	  
represent	  2-­‐5%	  of	  total	  tumor	  area	  at	  6	  weeks	  PI.	  Scale	  bar	  =	  50	  µm.	  	  B)	  Phospho-­‐ERK	  staining	  
in	   KM	   tumors	   harvested	   at	   6	   weeks	   PI	   (top	   and	   center	   panels)	   versus	   5	  months	   PI	   (bottom	  
panel).	  	  Scale	  bars	  =	  1	  mm	  (top	  and	  bottom	  panels)	  and	  200	  µm	  (center	  panel).	  	  C)	  Detection	  of	  
Hprt-­‐lsl-­‐IRFP	   expression	   in	   primary	   lung	   tumors	   (left)	   and	   a	   liver	   metastasis	   (right)	   in	   a	   KM	  
mouse	  harvested	  6	  months	  PI.	  Scale	  bar	  =	  5mm.	  	  D)	  Histological	  confirmation	  of	  liver	  metastasis	  
stained	  by	  H&E.	  E)	  IHC	  detection	  of	  SPC	  and	  p-­‐ERK	  in	  the	  same	  metastasis	  as	  (D).	  Scale	  bar	  =	  50	  
µm	  (D	  and	  E).	   	   Images	  are	   representative	  of	  6	  mice.	   	  F)	  Halo	  quantification	  of	  p-­‐ERK	  positive	  
cells	  in	  individual	  metastases,	  expressed	  as	  %	  of	  tumor	  cells.	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Figure	   3:	   Expression	  of	   the	   ERBB	  network	   increases	   during	  progression	   from	  p-­‐ERKlow	   to	   p-­‐
ERKhigh	  KM	  tumors	  
A)	  Normalized	   expression	   of	   RAS	   genes	   in	   laser-­‐capture	  micro-­‐dissected	   (LCM)	   p-­‐ERKHigh	   KM	  
tumor	   regions	   relative	   to	   p-­‐ERKLow	   regions	   from	   tumors	   in	   the	   same	   mice	   (n	   =	   4	   mice),	  
measured	   by	   RNA-­‐SEQ.	   False	   discovery	   rate	   (FDR)	   shown	   for	   KRAS;	   ns	   =	   not	   statistically	  
significant.	  	  B)	  Mean	  and	  SEM	  RNA-­‐SEQ	  reads	  of	  Ereg	  and	  Areg	  mRNA	  from	  p-­‐ERKLow	  &	  p-­‐ERKHigh	  
KM	  tumor	  regions	  from	  4	  mice.	  	  Adjusted	  p	  values	  were	  calculated	  in	  R.	  	  C)	  Serial	  sections	  of	  KM	  
tumors	  stained	  by	  IHC	  for	  p-­‐ERK	  (left	  panels)	  or	  by	  in	  situ	  hybridization	  for	  Ereg	  (center	  panels)	  
or	   Areg	   (right	   panels).	   Scale	   bars	   =	   200	   µm	   (upper	   panels)	   &	   25	   µm	   (lower	   panels).	   	   D)	  
Representative	   images	  of	  p-­‐ERK	   (IHC)	  and	  Areg	   (ISH)	  expression	   in	  KM	   liver	  metastasis.	   Scale	  
bar	   =	   200	   µm.	   Images	   are	   representative	   of	   4	   metastases	   with	   sufficient	   material.	   	   E)	  
Normalized	  expression	  of	  ERBB	  network	  genes	  showing	  mean	  fold	  increase	  (Δ)	  in	  expression	  in	  
p-­‐ERKHigh	  relative	  to	  p-­‐ERKLow	  KM	  tumor	  regions	  from	  4	  mice	  as	  per	  (A).	  	  FDR	  =	  false	  discovery	  
rate.	   	   F)	   Diagrammatic	   representation	   of	   up-­‐regulated	   components	   of	   the	   ERBB-­‐RAS-­‐ERK	  
pathway	  associated	  with	  KM	  tumor	  progression.	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Figure	   4:	   A	   feed-­‐forward	   ERBB	   signaling	   loop	   drives	   proliferation	   of	   KRAS-­‐mutant	   human	  
NSCLC	  cells	  
A)	  Growth	  curves	  of	  3	  KRAS-­‐mutant	  human	  NSCLC	  lines	  upon	  treatment	  with	  increasing	  doses	  
of	   the	   EGFR-­‐selective	   inhibitor	   erlotinib	   or	   the	   multi-­‐ERBB	   inhibitor,	   neratinib,	   measured	   by	  
Incucyte	   time-­‐lapse	   video-­‐microscopy.	   Error	   bars	   show	   SD	   for	   technical	   triplicates.	   Data	   are	  
representative	   of	   at	   least	   2	   independent	   experiments.	   	  B)	   Lysates	   from	   KRAS-­‐mutant	   NSCLC	  
cells	  treated	  with	  increasing	  doses	  of	  neratinib,	   immunoblotted	  with	  the	  indicated	  antibodies.	  	  
Asterisks,	  where	  present,	   indicate	  the	  correct	  band.	   	  C)	  RAS	  immunoblots	  of	  RAF-­‐coated	  bead	  
precipitates	   from	   lysates	   of	   A549	   cells	   treated	  with	   neratinib	   or	   vehicle	   control	   for	   2	   hours.	  	  
Lysate	   input	   aliquots	   were	   also	   immunoblotted	   with	   the	   indicated	   antibodies.	   	   Right	   panel	  
shows	  mean	  ±	  SEM	  for	  quantification	  of	  KRAS	  band	  intensities	  from	  3	  independent	  experiments	  
(arbitrary	  units).	  P	  values	  are	  from	  2-­‐tailed	  T-­‐tests.	  	  D)	  Top	  20	  significantly	  modulated	  pathways	  
associated	  with	  the	  transition	  to	  p-­‐ERKHigh	  disease	  in	  the	  KM	  model,	  identified	  using	  Metacore	  
GeneGO	  analysis	  of	  RNA-­‐SEQ	  expression	  data.	  	  Segment	  size	  in	  the	  pie	  chart	  (left	  panel)	  reflects	  
ranking	  of	  the	  pathways	  by	  false	  discovery	  rate	  (FDR).	  	  Right	  panels	  show	  that	  18	  of	  the	  same	  
pathways	   are	   modulated	   in	   each	   of	   3	   KRAS-­‐mutant	   human	   NSCLC	   lines	   after	   overnight	  
treatment	   with	   neratinib	   (250nM	   for	   A549	   and	   H2009;	   25nM	   for	   H358).	   Numbers	   and	   pie	  
segment	  size	  reflect	  ranking	  by	  FDR.	  	  E)	  Expression	  of	  ERBB	  ligands	  in	  the	  indicated	  cells	  treated	  
overnight	  with	  vehicle	  (black)	  or	  neratinib	  (red),	  measured	  by	  RNA-­‐SEQ	  as	  per	  (D).	  Mean	  &	  SEM	  
of	   biological	   triplicates	   shown.	   	   P	   values	   are	   from	   2-­‐tailed	   T-­‐tests,	   abbreviated	   as	   follows:	   *	  
=<0.05;	  **	  =	  <0.01;	  ***	  <0.0001;	  ns	  =	  not	  significant.	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Figure	   5:	   ERBB	   blockade	   enhances	  MEK	   inhibitor-­‐driven	   apoptosis	   in	   vitro	   and	   therapeutic	  
impact	  in	  vivo	  
A)	   Apoptosis	   induced	   in	   human	   NSCLC	   cells,	   measured	   48	   hours	   after	   treatment	   with	   the	  
indicated	   doses	   of	   neratinib	   (nera)	   and/or	   trametinib	   (tram).	  Mean	   ±	   SEM	  of	   3	   independent	  
experiments	  shown	  (ANOVA	  &	  Tukey	  test).	  	  B)	  Clonogenic	  assay	  showing	  suppression	  of	  colony	  
formation	   in	   A549	   and	   H358	   cells	   after	   48	   hours	   of	   treatment	  with	   the	   indicated	   inhibitors.	  
Lower	   panels	   show	   quantification	   of	   colony	   area	   (%	   surface	   coverage)	   from	   5	   independent	  
experiments.	   Significance	   was	   determined	   for	   drug	   combinations	   versus	   trametinib	   alone.	  
(ANOVA	  &	  	  Tukey	  test).	  	  C)	  Lysates	  from	  the	  indicated	  cells	  treated	  for	  24	  hours	  with	  increasing	  
doses	  of	  trametinib	  alone	  or	  the	  combination	  of	  trametinib	  and	  neratinib,	  immunoblotted	  with	  
the	   indicated	   antibodies.	   Asterisks,	   where	   present,	   indicate	   the	   correct	   band.	   	   D)	   Overall	  
survival,	  measured	  from	  the	  first	  day	  of	  treatment,	  of	  tumor-­‐bearing	  KM	  mice	  treated	  daily	  for	  
1	  week	  (tan	  bar)	  with	  neratinib	  (80	  mg/kg),	  trametinib	  (1	  mg/kg),	  or	  the	  combination	  of	  both,	  
then	  followed	  without	  further	  intervention.	  Treatment	  was	  commenced	  at	  5	  weeks	  PI.	  	  Cohorts	  
shown	   are	   vehicle	   (n=9);	   neratinib	   (n=7);	   trametinib	   (n=10);	   trametinib	   +	   neratinib	   (n=10).	  	  
Logrank	   hazard	   ratios	   (HR±95%	   CI)	   and	   p	   values	   are	   shown	   for	   comparisons	   of	   T+N	   versus	  
vehicle	   and	   T+N	   versus	   T	   alone	   (dashed	   lines).	   	   E)	   Lysates	   of	   individual	   tumors	   from	   mice	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Supplemental	  Materials	  
	  
Detailed	  Materials	  &	  Methods	  
Mice	  &	  in	  vivo	  procedures	  
The	   Hprt-­‐lsl-­‐IRFP	   allele	   was	   previously	   described	   [33].	   All	   mice	   were	   maintained	   on	   a	   mixed	  
FVBN/C57Bl6	  background,	  housed	  on	  a	  12-­‐hour	  light/dark,	  cycle	  and	  fed	  and	  watered	  ad	  libitum.	  	  
Recombinant	  adenoviruses	  expressing	  CRE	  (Ad-­‐CMV-­‐CRE	  &	  Ad5mSPC-­‐CRE)	  were	  purchased	  from	  
the	   University	   of	   Iowa	   gene	   therapy	   facility.	   For	   adeno-­‐CRE	   installation,	   young	   adult	   (8-­‐	   to	   10-­‐
week-­‐old)	  mice	  were	  sedated	  with	  a	  mixture	  of	  medetomidine	  and	  ketamine,	  injected	  IP.	  For	  most	  
experiments,	   1x107	   pfu	   adeno-­‐CRE	  were	   administered	   intranasally	   using	   the	   calcium	  phosphate	  
precipitation	  method,	  as	  described	  previously	  [35].	  For	  lower	  tumor	  burden,	  5x104-­‐3x105	  pfu	  were	  
administered.	  Neratinib	  (Medchem	  Express)	  was	  administered	  by	  twice-­‐daily	  gavage	  of	  40	  mg/kg	  
for	  up	  to	  4	  weeks,	  or	  a	  single	  daily	  IP	  injection	  of	  80	  mg/kg	  for	  short-­‐term	  (3-­‐7	  days)	  experiments.	  
Erlotinib	   (Apex-­‐Bio)	   was	   given	   by	   twice	   daily	   gavage	   of	   (50mg/kg).	   For	   gavage,	   0.5%	  
methylcellulose	   and	   0.4%	   Tween-­‐80	   in	   H2O	   was	   used	   as	   vehicle;	   peanut	   oil	   was	   used	   for	   IP.	  
Trametinib	  (LC	  Labs)	  was	  administered	  by	  single	  daily	  IP	  injection	  at	  1	  mg/kg.	  	  Live	  imaging	  of	  iRFP-­‐
positive	  tumor-­‐bearing	  mice	  was	  performed	  using	  a	  PEARL	  imaging	  system	  (Licor).	  	  All	  mice	  were	  
sacrificed	  humanely	  by	  CO2	  inhalation	  followed	  by	  cervical	  dislocation.	  
	  
Immunohistochemistry	  and	  Tissue	  Analysis	  
Mouse	   tissues	  were	  perfusion-­‐fixed	   in	   zinc	   formalin	  overnight.	   	  4-­‐µm	  paraffin	   sections	  were	  de-­‐
paraffinized	   and	   rehydrated:	   3	   x	   5	   minutes	   xylene,	   2	   minutes	   each	   in	   2x100%;	   2x95%;	   2x70%;	  
1x50%	  ethanol;	  dH2O.	  Peroxidase	  blocking	  was	  performed	  for	  10	  min	   in	  3%	  H2O2	  diluted	   in	  H2O,	  
followed	   by	   antigen	   retrieval	   in	   10	  mM	   citrate	   buffer,	   pH	   6,	   10	  min	   near	   boiling	   by	  microwave	  
heating	  at	  low	  power.	  Non-­‐specific	  antibody	  binding	  was	  blocked	  with	  up	  to	  3%	  BSA	  or	  up	  to	  5%	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normal	   goat	   serum	   for	   1	   hour	   at	   room	   temperature	   (RT)	   or	   overnight	   at	   40C.	   Primary	   antibody	  
incubation	  was	  performed	  overnight	  at	  40C	  or	  2	  hours	  at	  370C.	  Secondary	  biotinylated	  antibody	  
was	   incubated	   for	   1	   hour	   at	   room	   temperature,	   and	   the	   stain	  was	   developed	  with	   stable	   DAB	  
(Invitrogen)	   followed	   by	   counterstaining	   with	   Gil	   1	   hematoxylin	   (Sigma	  MH216)	   and	   Scotts	   tap	  
water	   substitute.	   	   The	   following	   antibodies	  were	   used	   at	   the	   indicated	   dilution:	   p-­‐ERK	   (P44/42	  
MAPK	   phospho-­‐Thr202/Tyr204),	   Cell	   Signaling	   CS4370,	   1:500;	   Ki67	   (Sp6),	   Fisher	   Scientific	  
RM9106S	  1:200;	  SP-­‐C,	  Millipore	  AB3786,	  1:1000;	  CC10,	  Millipore	  07-­‐623,	  1:1000;	  TUNEL	  ApopTag	  
kit,	  Millipore	   S7100;	   Vectorlabs	   VECTASTAIN	   ABC	   kit;	   anti-­‐rabbit	   IgG,	   PK-­‐4001	   ECL;	   anti-­‐rat,	   GE	  
Healthcare	  NA935.	  	  Ki67	  and	  TUNEL	  labeling	  was	  scored	  manually	  on	  5	  tumors	  from	  each	  mouse,	  
and	   graphs	   show	   mean	   values	   ±	   SE	   from	   the	   indicated	   number	   of	   mice.	   Tumor	   burden	   was	  
determined	  using	  Halo	   software	   (Indica	   Labs)	   as	   the	  %	   area	   of	   lung	   tissue	   occupied	   by	   tumors,	  
measured	  on	  hematoxylin	  &	  eosin	  (H&E)	  stained	  sections	  at	  100	  µm	  intervals	  through	  the	  entire	  
tissue	  block,	  from	  each	  of	  the	  indicated	  numbers	  of	  mice.	  Histological	  classification	  of	  tumors	  as	  
adenocarcinoma	   and	   identification	   of	   p-­‐ERKHigh-­‐	   and	   Areg-­‐expressing	   cells	   as	   epithelial	   was	  
performed	  independently	  by	  2	  clinical	  pathologists.	  
	  
In	  Situ	  Hybridization	  
5µm	   tissue	   sections	   on	   Superfrost	   Ultra	   plus	   slides	   were	   incubated	   at	   60oC	   for	   2	   hours.	   The	  
sections	  were	  then	  placed	  onto	  a	  Leica	  Bond	  Rx	  autostainer	  and	  stained	  overnight	  with	  the	  probe	  
of	   interest	   using	   a	   RNAscope	   2.5	   LS	   reagent	   brown	   kit	   (Leica	   Systems	   322100).	   	   The	   staining	  
protocol	   was	   fully	   automated	   and	   included	   the	   following	   steps:	   Dewaxing	   using	   Leica	   Bond	  
Dewaxn	  (AR9222)	  solution;	  washing	  with	  Leica	  Bond	  Wash	  solution	  (AR9590);	  Denaturing	  (antigen	  
retrieval)	   using	   Leica	   Bond	   Epitope	   Retrieval	   one	   solution	   (AR9661)	   at	   98oC	   for	   15	   followed	   by	  
rinsing	   in	  Bond	  Wash.	  Leica	  Enzyme	   III	   (AR9551)	  was	  applied	   for	  15	  minutes	   followed	  by	  rinsing	  
with	  Bond	  Wash.	  Areg-­‐	  or	  Ereg-­‐specific	  probes	  were	   incubated	   for	  2	  hours	  at	  40oC,	   followed	  by	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rinsing	  in	  Bond	  Wash.	   	  Sections	  were	  subject	  to	  6	  rounds	  of	  signal	  amplification	  using	  the	  2.5	  LS	  
reagent	  brown	  kit	   according	   to	  manufacturer’s	   instructions	   (Leica	   Systems).	  After	   application	  of	  
probe	  6,	  sections	  were	  rinsed	  and	  DAB	  solution	  from	  the	  2.5	  LS	  reagent	  kit	  applied	  to	  the	  sections	  
for	  20	  minutes	  at	  room	  temperature.	  Sections	  were	  then	  rinsed	  in	  water	  with	  haematoxylin	  and	  
bluing	  agent	  from	  the	  2.5	  LS	  kit	  applied	  to	  counterstain	  nuclei.	  Following	  standard	  dehydration	  in	  
graded	   alcohols,	   sections	  were	   	  mounted	  with	   a	   glass	   coverslip	   on	   a	   Leica	   CV5030	   coverslipper	  
using	  CellPath	  DPX	  mounting	  medium	  (SEA-­‐1300-­‐00A).	  
	  
Laser-­‐Capture	  Microdissection	  &	  RNA-­‐SEQ	  analysis	  
For	   micro-­‐dissection,	   10	  µm	   FFPE	   sections	   were	  mounted	   on	   framed	  membrane	   slides	   (Leica).	  	  
Adjacent	  sections	  were	  mounted	  on	  standard	  poly-­‐L-­‐lysine-­‐coated	  glass	  slides	  and	  stained	  for	  p-­‐
ERK.	  	  Membrane	  slide-­‐mounted	  tissue	  was	  de-­‐paraffinized,	  rehydrated,	  and	  stained	  with	  ice-­‐cold	  
1%	   cresyl	   violet.	   	   Selected	   tissue	  was	  micro-­‐dissected	  using	   a	   Leica	  DM	  6000B	  microscope,	   and	  
total	   time	   for	   staining	  and	  micro-­‐dissection	  was	  under	  20	  minutes	  per	   sample.	   	  P-­‐ERKLow	  and	  p-­‐
ERKHigh	  tumor	  regions	  were	  harvested	  into	  separate	  tubes,	  and	  tissue	  from	  multiple	  sections	  was	  
pooled	  for	  each	  of	  4	  mice.	  	  Harvested	  tissue	  was	  suspended	  in	  30	  µl	  PKD	  buffer	  (Qiagen,	  RNEasy	  
FFPE	   kit)	   and	   flash-­‐frozen	   for	   storage.	   	   Total	   tissue	  RNA	  was	   isolated	  using	   the	  RNEasy	   FFPE	   kit	  
according	   to	   manufacturer’s	   directions,	   and	   ribosomal	   RNA	   was	   depleted	   with	   Ribo-­‐Zero	  
(Epicentre).	  Synthesis	  of	  cDNA	  was	  performed	  using	  the	  SMARTER	  Stranded	  random	  primed	  RNA-­‐
SEQ	  kit	   (Takara/Clontech),	   resulting	   in	  cDNA	   libraries	   flanked	  by	   Illumina	   indexing	  primers.	  After	  
library	  quantification	  (Quant-­‐IT	  Pico	  green	  kit,	   Invitrogen),	   libraries	  were	  standardized	  to	  10	  nM,	  
denatured,	  diluted	  to	  10	  pM,	  and	  analyzed	  by	  paired-­‐end	  sequencing	  with	  an	  Illumina	  GA11X	  deep	  
sequencer.	  	  The	  raw	  RNA-­‐sequencing	  data	  files	  underwent	  quality	  checks	  using	  FastQC	  and	  FastQ-­‐
Screen	  software.	  RNA-­‐sequencing	   reads	  were	  aligned	   to	   the	  GRCm38	   [42]	  version	  of	   the	  mouse	  
genome	  using	  Tophat2	  version	  2.0.10	  [43]	  with	  Bowtie	  version	  2.1.0	  [44].	  Relative	  expression	  was	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determined	   and	   statistically	   analyzed	   by	   a	   combination	   of	  HTSeq	   and	   the	   R	   3.0.2	   environment,	  
using	  packages	  from	  the	  Bioconductor	  data	  analysis	  suite	  and	  differential	  gene	  expression	  analysis	  
based	   on	   the	   negative	   binomial	   distribution	   in	   the	   EdgeR	   package	   [45].	   	   Pathway	   modulation	  
analysis	   was	   performed	  with	  Metacore	   GeneGO	   (Thompson	   Reuters).	   For	   analysis	   of	   individual	  
gene	   expression,	   data	   were	   normalized	   to	   B2m	   for	   each	   mouse,	   and	   fold	   change	   and	   false	  
discovery	  rates	  were	  recalculated.	  	  RNA-­‐SEQ	  analysis	  of	  human	  cell	   lines:	  Total	  RNA	  was	  isolated	  
using	   the	   RNEasy	   Mini	   Kit	   (Qiagen)	   according	   to	   manufacturer’s	   instructions,	   and	   DNA	   was	  
depleted	   with	   the	   RNase-­‐Free	   DNase	   Set	   (Qiagen).	   RNA	   integrity	   was	   checked	   using	   the	   RNA	  
ScreenTape	   assay	   (Agilent	   Technologies),	   and	   cDNA	  was	   synthesized	   with	   the	   TruSeq	   Stranded	  
mRNA	   Library	   Prep	   Kit	   (Illumina).	   After	   library	   quantification	   (D1000	   ScreenTape,	   Agilent	  
Technologies),	  libraries	  were	  standardized	  to	  10	  nM,	  denatured,	  diluted	  to	  10	  pM,	  and	  analyzed	  by	  
paired-­‐end	   sequencing	   using	   an	   Illumina	   NextSeq500	   platform.	   RNA-­‐Sequencing	   reads	   were	  
aligned	  to	  the	  GRCh37	  version	  of	  the	  human	  genome	  and	  differential	  expression	  determined	  with	  
DESeq2	  [46].	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Figure	  S1:	  Characterization	  of	  KM	  lung	  tumors.	  	  	  
A)	  Schematic	  of	  allele	  activation:	  	  Adult	  (8-­‐	  to	  10-­‐week-­‐old)	  mice	  bearing	  the	  indicated	  conditional	  
alleles	   were	   given	   recombinant	   adeno-­‐CRE	   via	   intranasal	   instillation	   and	   monitored	   for	   the	  
durations	   indicated	   in	  the	  text,	  or	  until	  symptomatic.	   	  B)	   Immunoblots	  of	   lysates	  from	  individual	  
KM	  tumors	  induced	  with	  Ad5mSPC-­‐CRE	  (lanes	  1&2)	  and	  treated	  with	  neratinib	  (lane	  2),	  compared	  
with	   normal	   lung	   (lane	   3).	   	   C)	   Serial	   sections	   from	   an	   lsl-­‐KRasG12D;R26-­‐lsl-­‐MYCHom	   mouse	   lung	  
harvested	   at	   6	   weeks	   post	   induction	   (PI)	   and	   stained	   with	   the	   indicated	   antibodies	   or	   TUNEL.	  	  
Scale	  bars	  =	  50	  µm.	   	   Images	  are	   representative	  of	   lungs	   from	  at	   least	  5	  mice	  analyzed	   for	  each	  
stain.	   	  Outline	  demarcates	   the	  approximate	  p-­‐ERK-­‐positive	   tumor	   region.	   	  D)	  Workflow	  of	   laser-­‐
capture	  micro-­‐dissection	  (LCM)	  of	  FFPE	  KM	  lung	  tumors.	   	  Serial	  sections	  were	  first	  stained	  for	  p-­‐
ERK	   expression	   to	   identify	   p-­‐ERKHigh	   and	   p-­‐ERKLow	   tumor	   regions.	   	   Cresyl	   violet-­‐stained	   adjacent	  
sections	  were	  then	  subject	  to	  LCM	  upon	  identification	  of	  the	  corresponding	  regions.	   	  Messenger	  
RNA	   was	   purified	   from	   harvested	   material	   and	   analyzed	   by	   RNA-­‐SEQ.	   	   E)	   Gene	   signature	   of	  
progression	  from	  p-­‐ERKLow	  to	  p-­‐ERKHigh	  KM	  tumors	  triaged	  to	  only	   include	  genes	  either	  amplified	  
or	  overexpressed	  in	  human	  LuAd	  data	  sets	  [2,	  8,	  9,	  47].	  	  Results	  from	  4	  mice	  shown.	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Figure	  S2:	  Comparison	  of	  KM	  phenotype	  induced	  by	  Ad-­‐CMV-­‐CRE	  &	  Ad-­‐SPC-­‐CRE	  	  
A)	  Serial	  sections	  show	  representative	  images	  of	  KM	  lungs	  induced	  by	  the	  indicated	  CRE-­‐delivery	  
vectors	   harvested	   and	   analyzed	   at	   6	   weeks	   post	   induction.	   H&E,	   IHC	   for	   p-­‐ERK	   and	   F4/80	  
(macrophages),	   along	  with	   ISH	   for	  Areg	  mRNA	   are	   shown.	   	   Scale	   bars	   =	   100	  µm.	  B)	  Additional	  
examples	  of	  IHC	  and	  Areg	  ISH	  in	  primary	  lung	  tumors	  from	  Ad-­‐CMV-­‐CRE	  and	  Ad-­‐SPC-­‐CRE	  induced	  
KM	   mice.	   Scale	   bars	   =	   100	   µm.	   C)	   Additional	   examples	   of	   p-­‐ERK	   IHC	   and	   Areg	   ISH	   in	   liver	  
metastases	  from	  KM	  mice.	  	  Scale	  bars	  =	  25	  µm.	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Figure	  S3:	  Genomic	  alterations	  and	  expression	  of	  ERBB	  network	  genes	   in	  human	  KRAS-­‐mutant	  
lung	  adenocarcinoma.	  	  	  
Each	  column	  represents	  an	  individual	  tumor.	  	  Genes	  are	  grouped	  as	  ERBB	  ligands,	  ERBB	  RTKs	  and	  
ERBB	   accessory	   proteins.	   Percentages	   refer	   to	   the	   frequency	   of	   alteration	   across	   all	   lung	  
adenocarcinomas.	  	  Orange	  bars	  (top)	  emphasize	  cases	  with	  KRAS	  mutations	  (n=74,	  of	  which	  73	  are	  
codon	  12	  mutant),	   and	  orange	  boxes	  outline	   the	  ERBB	  network	   in	   the	   same	  cases.	   	  Green	  dots	  
indicate	  codon	  alterations;	  black	  dots	   indicate	   truncation	  mutations;	   solid	   red	  bars	  denote	  gene	  
amplifications;	   open	   red	   bars	   show	   increased	   mRNA	   expression;	   solid	   blue	   bars	   indicate	   deep	  
deletions.	  	  Gray	  bars	  indicate	  no	  detected	  alteration.	  	  Data	  are	  derived	  from	  the	  published	  TCGA	  
lung	  adenocarcinoma	  cohort	  as	  accessed	  via	  cBioportal	  (truncated	  from	  the	  right	  to	  focus	  on	  the	  
KRAS-­‐mutated	  patient	  subset).	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Figure	  S4:	  Sensitivity	  of	  KRAS	  mutant	  cell	  lines	  to	  ERBB	  blockade.	  	  	  
A)	   Lysates	   from	  KRAS-­‐mutant	  NSCLC	  cells	   treated	  with	   increasing	  doses	   (10,	  100,	  500	  and	  1000	  
nM)	   of	   erlotinib	   or	   neratinib	  were	   subject	   to	   immunoblotting	  with	   the	   indicated	   antibodies.	  B)	  
Growth	  curves	  of	  KrasG12D/wt;p53R270H/-­‐	  (single	  copy	  KRasG12D)	  and	  KrasG12D/HCG;p53R270H/-­‐	  [high	  copy	  
gain	   (HCG)	  KRasG12D]	  murine	   lung	   tumor	   cell	   lines	   treated	  with	   the	   indicated	  doses	   of	   neratinib	  
(upper	   panels)	   or	   erlotinib	   (lower	   panels),	  monitored	   by	   Incucyte	   time	   lapse	   video-­‐microscopy.	  	  
Error	   bars	   denote	   SD	   of	   technical	   triplicates.	   	  C)	   Growth	   curves	   of	   RAS-­‐less	  MEFs	   reconstituted	  
with	  wt	  	  (left	  panel)	  or	  G12D	  mutant	  (center	  panel)	  KRAS	  and	  treated	  with	  the	  indicated	  doses	  of	  
neratinib.	   	   Error	  bars	   indicate	  SEM	  of	  biological	   triplicates.	   	  Right	  panel	   shows	  p-­‐ERK	  and	  p-­‐AKT	  
immunoblots	  of	  lysates	  from	  KRASG12D-­‐expressing	  MEFs	  treated	  with	  or	  without	  neratinib.	  	  D)	  RAF-­‐
RBD	  binding	  assay	   in	  RAS-­‐less	  MEFs	  reconstituted	  with	  KRAS	  G12D,	  treated	  with	  1	  µM	  neratinib	  
(nera)	  or	  vehicle	  control	  (vc),	  immunoblotted	  with	  pan-­‐RAS	  or	  KRAS-­‐specific	  antibodies.	  The	  right	  
panel	  shows	  quantification	  from	  3	  independent	  experiments	  (T-­‐Test).	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Figure	  S5:	  Longitudinal	  in	  vivo	  imaging	  of	  nascent	  lung	  tumors.	  	  	  
A)	   Quantification	   of	   cell	   death	   in	   KRAS-­‐mutant	   human	   lung	   cancer	   lines	   upon	   treatment	   with	  
neratinib	  (250	  nM;	  upper	  panels)	  or	  afatinib	  (1	  µM;	  lower	  panels),	  alone	  or	  in	  combination	  with	  2	  
doses	   (10	   nM	   or	   100	   nM)	   of	   the	   MEK	   inhibitor	   trametinib.	   	   Mean	   and	   SEM	   values	   from	   a	  
representative	  experiment	  are	  shown.	  ns	  =	  not	  significant.	   	   Lower	  doses	  of	  drugs	  were	  used	   for	  
H358	  cells	  (50	  nM	  afatinib	  or	  neratinib	  and	  10	  or	  50	  nM	  trametinib)	  due	  to	  their	  greater	  sensitivity	  
to	   each	   drug	   alone.	   	  B)	   KM	  mice	  were	   interbred	  with	  Hprt-­‐lsl-­‐iRFP,	   induced	  with	   adeno-­‐CRE	   as	  
before,	   and	  monitored	   for	   tumor	   growth	   using	   a	   Licor	   PEARL	   imager.	   	   Circles	   indicate	   days	   of	  
imaging.	   Data	   are	   normalized	   to	   background	   fluorescence	   for	   each	  mouse,	   set	   to	   0,	   and	   signal	  
intensity	   curves	   were	   calculated	   using	   the	   Weibull	   growth	   equation	   (Graphpad	   Prism).	   Upon	  
consistent	  detection	  of	  pulmonary	  fluorescence,	  MDAL6-­‐1F	  was	  treated	  with	  the	  combination	  of	  
neratinib	  +	  trametinib,	  while	  MDAL5.1D	  and	  MDAL6.1A	  received	  vehicle	  control	  for	  1	  week	  (gray	  
bar).	   	   The	  presence	  of	   tumors	  was	   confirmed	  upon	   sacrifice.	   	  C)	  Representative	   images	  of	  mice	  
treated	  as	  per	  (B)	  showing	  fluorescent	  detection	  of	  iRFP-­‐labeled	  KM	  tumors	  before	  and	  after	  drug	  
(or	  vehicle)	  treatment.	  The	  same	  colorimetric	  scale	  was	  used	  for	  each	  image.	  	  Images	  are	  cropped	  
to	  show	  only	  the	  chest	  area.	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Table	  S1	  
	  
Table	  S1:	  Summary	  of	  Metacore	  GeneGO	  pathway	  analysis.	  	  	  
The	   blue	   shaded	   region	   demarcates	   pathways	   modulated	   as	   KM	   tumors	   progress	   to	   pERKHigh	  
expression,	  ranked	  by	  false	  discovery	  rate	  (FDR).	  	  The	  beige	  shaded	  region	  indicates	  the	  rank	  and	  
FDR	  of	  the	  same	  pathways	  upon	  treatment	  of	  the	  indicated	  KRAS-­‐mutant	  human	  NSCLC	  cell	  lines	  
with	  neratinib.	  	  	  
Modulated	  during	  progression	  to	  p-­‐ERK	  +	  tumors	   Modulated	  by	  neratinib	  in	  vitro	  
	   H358	   H2009	   A549	  
Pathway	   Rank	   FDR	   Rank	   FDR	   Rank	   FDR	   Rank	   FDR	  
Cytoskeletal	  remodeling,	  TGF,	  WNT	  pathways	   1	   1.70E-­‐24	   1	   2.70E-­‐26	   1	   1.50E-­‐26	   1	   2.30E-­‐27	  
Cytoskeletal	  remodeling	   2	   9.00E-­‐23	   2	   3.20E-­‐21	   2	   2.10E-­‐22	   4	   2.40E-­‐22	  
Transport	  -­‐	  Clathrin-­‐coated	  vescicle	  cycle	   3	   3.60E-­‐19	   3	   2.50E-­‐18	   3	   2.20E-­‐21	   2	   1.40E-­‐22	  
Apoptosis	  &	  survival,	  NGF/TrkA	  PI3K	  signaling	   4	   1.40E-­‐15	   4	   4.40E-­‐17	   4	   7.80E-­‐19	   3	   1.60E-­‐22	  
Transcription,	  Sin3	  &	  NuRD	  regulated	   5	   1.60E-­‐15	   8	   4.90E-­‐16	   6	   4.10E-­‐17	   6	   4.90E-­‐18	  
Immune	  Response,	  IL4	  signaling	   6	   9.10E-­‐15	   19	   2.60E-­‐13	   14	   6.60E-­‐15	   8	   7.10E-­‐17	  
Cell	  Cycle,	  influence	  of	  Ras	  &	  Rho	  in	  G1/S	   7	   2.70E-­‐14	   11	   7.80E-­‐15	   8	   5.20E-­‐16	   7	   5.80E-­‐17	  
Cell	  Adhesion,	  Chemokines	  &	  adhesion	   8	   2.80E-­‐14	   7	   2.30E-­‐16	   17	   1.50E-­‐14	   19	   1.10E-­‐13	  
Development,	  TGF-­‐beta	  receptor	  signaling	   10	   2.30E-­‐13	   6	   2.10E-­‐16	   5	   1.20E-­‐17	   13	   1.20E-­‐14	  
Translation,	  regulation	  of	  EIF4F	  activity	   11	   3.20E-­‐13	   14	   1.10E-­‐13	   13	   6.60E-­‐15	   14	   1.20E-­‐14	  
Development,	  EGFR	  signaling	   12	   4.40E-­‐13	   12	   1.90E-­‐14	   10	   6.70E-­‐16	   11	   4.30E-­‐15	  
Receptor	  mediated	  axon	  growth	  repulsion	   13	   5.40E-­‐13	   26	   3.00E-­‐12	   21	   3.00E-­‐13	   10	   3.40E-­‐15	  
Androgen	  receptor	  activation	   14	   5.60E-­‐13	   5	   7.60E-­‐17	   16	   1.10E-­‐14	   15	   1.20E-­‐14	  
Epigenetic	  regulation	  of	  gene	  expression	   16	   1.60E-­‐12	   21	   5.60E-­‐13	   22	   3.40E-­‐13	   16	   5.00E-­‐14	  
IGF	  family	  signlaing	  in	  colorectal	  cancer	   17	   1.60E-­‐12	   22	   5.60E-­‐13	   18	   3.20E-­‐14	   29	   2.20E-­‐12	  
TGFb-­‐dependent	  induction	  of	  EMT	  via	  MAPK	   18	   1.60E-­‐12	   31	   7.60E-­‐12	   25	   7.40E-­‐13	   26	   1.60E-­‐12	  
NGF/TrkA	  MAPK-­‐mediated	  signaling	   19	   2.10E-­‐12	   9	   1.30E-­‐15	   9	   6.70E-­‐16	   9	   9.00E-­‐16	  
Regulation	  of	  STK3/4	  (Hippo)	  and	  YAP/TAZ	   20	   2.90E-­‐12	   18	   2.60E-­‐13	   15	   1.10E-­‐14	   12	   9.40E-­‐15	  
